论文部分内容阅读
目的:研究肿瘤热休克蛋白70(HSP70)与IL-2联合应用对荷瘤小鼠的治疗作用。方法:用液相色谱法纯化小鼠肿瘤细胞 株中的HSP70。对纯化产物用SDS-PAGE及Western blot进行定性分析,再用毛细管电泳鉴定其纯度。通过动物实验,观察HSP70与IL-2单独应用及联合应用的抗肿瘤作用。结果:HSP70与IL-2联合应用较单独应用的治疗效果更明显,但治疗作用仍以HSP70为主。单独应用IL-2只能延长小鼠的生存期限[平均为(36.6±13.0)d],而HSP70 10μg组可使40％荷瘤小鼠的肿瘤最终全部消退,生存期最长者>90[平均生存期(>59.2±29.6)d],与对照组相比较差异显著(P<0.01)。HSP70与IL-2联合应用组可使60％荷瘤小鼠的肿瘤完全消退,平均生存期(>70.8±26.5)d,与对照组相比差异十分显著(P<0.01)。结论:合适剂量的HSP70与IL-2联合应用,对荷瘤小鼠有明显的治疗作用,可明显抑制肿瘤进展,提高生存率。以上结果对研究人类恶性肿瘤的免疫治疗具有较大的参考价值。
Objective: To study the therapeutic effect of combined application of tumor heat shock protein 70 (HSP70) and IL-2 on tumor-bearing mice. Methods: HSP70 was purified from mouse tumor cell lines by liquid chromatography. The purified product was qualitative analyzed by SDS-PAGE and Western blot, and then its purity was identified by capillary electrophoresis. Animal experiments were conducted to observe the antitumor effects of HSP70 and IL-2 alone and in combination. Results: The combination of HSP70 and IL-2 was more effective than single treatment, but the therapeutic effect was still mainly HSP70. Treatment with IL-2 alone prolonged survival in mice (mean, 36.6 ± 13.0 days), whereas HSP70 10 μg resulted in the complete regression of tumors in 40% of tumor-bearing mice, with the longest survival being> 90 [ The mean survival time (> 59.2 ± 29.6 days) was significantly higher than that in the control group (P <0.01). The combination of HSP70 and IL-2 could completely eliminate tumor in 60% of tumor-bearing mice. The average survival time (> 70.8 ± 26.5) d was significantly different from that in control group (P <0.01). Conclusion: The combination of HSP70 and IL-2 at a suitable dosage has significant therapeutic effect on tumor-bearing mice, which can significantly inhibit tumor progression and improve survival rate. The above results for the study of human immunodeficiency disease has a greater reference value.